Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.

Marta ZolaAlejandra Daruich Alexandre Matet Irmela MantelFrancine Behar-Cohen

Published in: The British journal of ophthalmology (2018)

The visual and anatomical benefit of MRa treatment prolonged for 6 months or more in chronic, non-resolving CSC appeared to be maintained over a 24-month period. These results suggest that MRa can be proposed as an alternative therapy in severe CSC with advanced RPE alterations.

Keyphrases

contrast enhanced
high grade
drug induced
early onset
stem cells
combination therapy
bone marrow
cell therapy